Persistent dysregulation of IgA production and IgA nephropathy in the B6C3F1 mouse following withdrawal of dietary vomitoxin (deoxynivalenol).
To assess whether vomitoxin-induced dysregulation of IgA production and IgA nephropathy are reversible, relevant immunologic parameters were compared among experimental groups of B6C3F1 mice that were fed: (1) 25 ppm vomitoxin in AIN-76A semipurified diet for 24 weeks (treatment group), (2) 25 ppm vomitoxin for 8 weeks and then control diet for 16 weeks (withdrawal group), and (3) control diet for 24 weeks (control group). Levels of serum IgA and microhematuria index in the treatment group were elevated after 4 to 8 weeks and continued to increase with further vomitoxin exposure. IgA immune complexes and mesangial IgA deposition, as quantitated by interactive laser cytometer image analysis, were also increased with toxin exposure at Weeks 8, 16, and 24, whereas IgM, IgG, and complement component C3 deposition were unaffected or depressed. Serum IgA, microhematuria index, and mesangial IgA deposition in withdrawal mice remained elevated over those of the controls at Weeks 16 and 24 but were less than those of the treatment group. Cell recovery from Peyer's patches (PP) as well as the percentages of IgA+ and CD4+ cells in PP and spleen at Weeks 16 and 24 were greater in treatment mice than in controls, but only the percentage of IgA+ cells in PP was elevated in the withdrawal mice at these the same time points. When IgA secretion by unstimulated and LPS-stimulated splenic lymphocytes was used as the measure of systemic production, it was elevated in both treatment and withdrawal mice at Weeks 16 and 24. The results indicated that experimental dysregulation of IgA production and IgA nephropathy persisted up to 4 months after a discrete period of dietary vomitoxin exposure, but that the severity of these effects did not increase in a progressive fashion.
Dong
W
W
Department of Food Science and Human Nutrition, Michigan State University, East Lansing 48824.
Pestka
J J
JJ
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015704:CD4 Antigens / Q000276:immunology; D003176:Complement C3 / Q000096:biosynthesis; D005260:Female; D005922:Glomerulonephritis, IGA / Q000139:chemically induced / Q000276:immunology*; D006417:Hematuria / Q000139:chemically induced; D007105:Immune Complex Diseases / Q000139:chemically induced; D007070:Immunoglobulin A / Q000096:biosynthesis*; D007958:Leukocyte Count / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D011507:Proteinuria / Q000139:chemically induced; D014255:Trichothecenes / Q000633:toxicity*
D015704:CD4 Antigens; D003176:Complement C3; D007070:Immunoglobulin A; D014255:Trichothecenes; C007262:deoxynivalenol